Clinical Psychopharmacology and Neuroscience最新文献_第8页

Predicting and Early Detection of Delirium through Motion Patterns: A Narrative Review. 通过运动模式预测和早期检测谵妄：叙述回顾。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-12-09 DOI: 10.9758/cpn.25.1326

Ji Sun Hong, Na Yeon Kim, Hye Ri Kim, Doug Hyun Han, Sun Mi Kim

{"title":"Predicting and Early Detection of Delirium through Motion Patterns: A Narrative Review.","authors":"Ji Sun Hong, Na Yeon Kim, Hye Ri Kim, Doug Hyun Han, Sun Mi Kim","doi":"10.9758/cpn.25.1326","DOIUrl":"10.9758/cpn.25.1326","url":null,"abstract":"Delirium is a common acute neuropsychiatric syndrome, and its early detection may improve clinical outcomes. This narrative review synthesized findings from 11 original studies and two systematic reviews that employed wearable sensors (actigraphy) to predict or detect delirium. In surgical, intensive care unit, and geriatric populations, delirium has consistently been associated with disrupted rest-activity rhythms, including lower daytime activity, increased nighttime activity, and fragmented sleep-wake cycles. Characteristic motor patterns also differed based on the motor subtype (hyperactive vs. hypoactive). Several studies have demonstrated that continuous wrist accelerometry can objectively detect the onset of delirium and classify motor subtypes. Notably, one machine learning model showed improved prediction accuracy, increasing from approximately 62% to 74% when motion features were included. Overall, continuous motion monitoring appears feasible and may serve as a promising non-invasive tool for early delirium detection and risk stratification. However, the findings remain heterogeneous, and motion-based algorithms alone show only moderate sensitivity. Further validation in larger and more diverse cohorts, as well as integration with clinical risk factors, is required before clinical implementation.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"30-39"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Testosterone on Maintenance of Morphine-induced Conditioned Place Preference: Androgen and μ-opioid Receptor Gene Expressions in PFC and NAc of Rats. 睾酮对吗啡诱导的条件位置偏好维持的影响：大鼠PFC和NAc中雄激素和μ-阿片受体基因的表达。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 DOI: 10.9758/cpn.25.1348

Nader Charkhgard, Anahita Torkaman-Boutorabi, Maryam Zahmatkesh, Nasim Vousooghi, Maryam Farahmandfar, Nasim Nadi Moghadam

{"title":"Effect of Testosterone on Maintenance of Morphine-induced Conditioned Place Preference: Androgen and μ-opioid Receptor Gene Expressions in PFC and NAc of Rats.","authors":"Nader Charkhgard, Anahita Torkaman-Boutorabi, Maryam Zahmatkesh, Nasim Vousooghi, Maryam Farahmandfar, Nasim Nadi Moghadam","doi":"10.9758/cpn.25.1348","DOIUrl":"10.9758/cpn.25.1348","url":null,"abstract":"Objective: Rewarding properties of androgens have been suggested. This research aimed to assess the effect of androgen system during the extinction period on morphine induced conditioned place preference (CPP). Androgen and μ-opioid receptor (μ-OR) gene expression were also evaluated in prefrontal cortex (PFC) and nucleus accumbens (NAc) in the male rats.Methods: CPP was induced by morphine injection (3, 5 and 7 mg/kg, s.c.) for three consecutive days. Testosterone (androgen receptor [AR] agonist, 2.5 mg/kg; i.m.) or flutamide (AR antagonist 10 mg/kg, i.m.) were administered in subsequent extinction period. In two castration groups, one group was considered as control and the other one received testosterone during extinction phase. The mRNA expression levels of μ-OR and ARs in PFC and NAc were evaluated using quantitative real-time PCR following CPP reinstatement.Results: Testosterone prolonged while flutamide shortened extinction period. Castration facilitated morphine-extinction and testosterone could not reverse this effect. The expression of μ-OR and ARs were increased in PFC and NAc of castrated animals compared to control group which were reversed by testosterone. This effect was not reversed by testosterone for μ-OR in PFC.Conclusion: Our data indicated that decreased level of testosterone facilitates extinction period in morphine CPP model in male rats. This result could be due to the changes in the expression of opioid and androgenic receptors in PFC and NAc. This study confirms the crucial role of androgen system in modulating drug reward.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"166-176"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction of Reward Processing Deficits in Youth with Disruptive Behavior and Trauma Exposure: A Pilot Study of Neural Responses to Fluoxetine. 具有破坏性行为和创伤暴露的青少年奖励加工缺陷的纠正：氟西汀神经反应的初步研究。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-10-29 DOI: 10.9758/cpn.25.1336

Soonjo Hwang, Unsun Chung, Ji-Woo Suk, Stuart White, Ellen Leibenluft, Robert James Richard Blair

{"title":"Correction of Reward Processing Deficits in Youth with Disruptive Behavior and Trauma Exposure: A Pilot Study of Neural Responses to Fluoxetine.","authors":"Soonjo Hwang, Unsun Chung, Ji-Woo Suk, Stuart White, Ellen Leibenluft, Robert James Richard Blair","doi":"10.9758/cpn.25.1336","DOIUrl":"10.9758/cpn.25.1336","url":null,"abstract":"Objective: Youths with disruptive behavior disorders (DBDs) and a history of trauma exposure often exhibit deficits in neural mechanisms related to reward anticipation and assessment. This preliminary investigation examines the potential of a serotonergic agent (fluoxetine) to modulate neural activity in reward-related pathways for this population.Methods: Three participant groups were: (i) youth with DBDs and trauma exposure who received fluoxetine treatment for 8 weeks (n = 12); (ii) a matched group of youth with DBDs and trauma exposure who received routine regular follow-up in an outpatient clinic (n = 9); and (iii) typically developing youth (n = 19). All participants completed a passive avoidance fMRI task twice, 8 weeks apart (pre-treatment and post treatment for youth with DBDs).Results: Youth with DBDs and trauma exposure who received fluoxetine treatment compared to the other two groups showed: (i) significant improvement in externalizing, oppositional defiant disorder, irritability, anxiety-depression, and trauma-related symptoms; (ii) significantly increased recruitment of regions implicated in reward expectation (e.g., ventral tegmental area, nucleus accumbens), monitoring prediction error (e.g., dorsolateral prefrontal cortex, posterior parietal cortex), and inhibitory control (e.g., anterior insula, pre-supplementary motor area, anterior prefrontal cortex.Conclusion: We provide preliminary data suggesting that a serotonergic medication can correct reward processing and provide symptom improvement in youth with DBDs and a history of trauma exposure. Given the small sample size, more rigorous studies with larger sample size are needed to confirm these results. The findings of this study could aid future clinical research and treatment for this challenging population.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"129-139"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combining Three Long-acting Injectable Antipsychotics: A Case Series. 三种长效注射抗精神病药物的联合应用：一个案例系列。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-12-22 DOI: 10.9758/cpn.25.1311

Ayşe Nur İnci Kenar, Selin Balki Tekin

{"title":"Combining Three Long-acting Injectable Antipsychotics: A Case Series.","authors":"Ayşe Nur İnci Kenar, Selin Balki Tekin","doi":"10.9758/cpn.25.1311","DOIUrl":"10.9758/cpn.25.1311","url":null,"abstract":"The decision to use multiple long-acting injectable antipsychotics (LAIAs) is difficult since there is no evidence base for their use in treatment guidelines. In this case series, we aimed to present our experiences with the use of triple LAIAs in four patients diagnosed with schizophrenia. The study included four treatment-resistant schizophrenia cases who were followed in the inpatient ward of a university hospital, who could not use clozapine due to non-compliance with treatment, who did not benefit from multiple electroconvulsive therapy procedures, who did not respond to dual antipsychotic treatments and who were using triple LAIAs. The clinical histories of the cases were analysed retrospectively by experienced psychiatrists. All patients responded to the treatment with a decrease in their psychotic symptoms and the number of hospitalizations without any significant side effects. Also, improvement in daily functioning and adherence to treatment was observed in all cases. Based on these results, the use of multiple LAIAs can be safely applied, especially in appropriate treatment-resistant schizophrenia patients and with close follow-up by a clinician.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"192-196"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Korean Medication Algorithm Project for Depressive Disorder 2025: Comparisons with Other Treatment Guidelines. 韩国抑郁症药物算法项目2025：与其他治疗指南的比较。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-10-01 DOI: 10.9758/cpn.25.1330

Won-Seok Choi, Young Sup Woo, Won-Myong Bahk, Nak-Young Kim, Jeong Seok Seo, Sheng-Min Wang, Won Kim, Sung-Yong Park, Jung Goo Lee, Chan-Mo Yang, Hyung Mo Sung, Young-Eun Jung, Moon-Doo Kim, Jong-Hyun Jeong, Bo-Hyun Yoon, Kyung Joon Min

{"title":"Korean Medication Algorithm Project for Depressive Disorder 2025: Comparisons with Other Treatment Guidelines.","authors":"Won-Seok Choi, Young Sup Woo, Won-Myong Bahk, Nak-Young Kim, Jeong Seok Seo, Sheng-Min Wang, Won Kim, Sung-Yong Park, Jung Goo Lee, Chan-Mo Yang, Hyung Mo Sung, Young-Eun Jung, Moon-Doo Kim, Jong-Hyun Jeong, Bo-Hyun Yoon, Kyung Joon Min","doi":"10.9758/cpn.25.1330","DOIUrl":"10.9758/cpn.25.1330","url":null,"abstract":"The sixth edition of the Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) was published in 2025. This review compared KMAP-DD 2025 with four major international clinical practice guidelines: Canadian Network for Mood and Anxiety Treatments Clinical Guidelines for the Management of Major Depressive Disorders, National Institute for Health and Care Excellence Depression Guideline, Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders, and British Association for Psychopharmacology Guideline. While KMAP-DD is based on expert consensus, and others on evidence-based methods, overall treatment strategies for depressive episodes were fairly consistent. Especially, KMAP-DD 2025 offers more structured recommendations in areas lacking strong evidence, such as premenstrual dysphoric disorder, perinatal depression, and depression with medical comorbidities. KMAP-DD 2025 also reflected Korean clinical practice patterns emphasizing rapid symptom relief and early use of combination strategies. Despite limitations as a consensus-based guideline, KMAP-DD 2025 complements evidence-based approaches and provides practical, situation-specific guidance for real-world clinical decision-making in Korea.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"2-14"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum Levels of Wnt/β-catenin Pathway Regulators Dkk-1, PORCN, Notum, and Tiki-1 in Children with Autism Spectrum Disorder. 自闭症谱系障碍儿童Wnt/β-连环蛋白通路调节因子Dkk-1、PORCN、Notum和Tiki-1的血清水平

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-07-28 DOI: 10.9758/cpn.25.1323

Fatma Coşkun, Ayşegül Tuğba Hira Selen, İbrahim Kılınç, Ahmet Osman Kılıç

{"title":"Serum Levels of Wnt/β-catenin Pathway Regulators Dkk-1, PORCN, Notum, and Tiki-1 in Children with Autism Spectrum Disorder.","authors":"Fatma Coşkun, Ayşegül Tuğba Hira Selen, İbrahim Kılınç, Ahmet Osman Kılıç","doi":"10.9758/cpn.25.1323","DOIUrl":"10.9758/cpn.25.1323","url":null,"abstract":"Objective: Dysregulation of the Wnt/β-catenin signaling system has been increasingly associated with the pathogenesis of autism spectrum disorder (ASD). Nevertheless, regulators of this system remain unexamined in patients with ASD. This study aimed to examine serum concentrations of Dkk-1, PORCN, Notum, and Tiki-1 in preschool children with ASD.Methods: A total of 60 children diagnosed with ASD and 50 healthy controls, aged 18 to 60 months, were included in the study. Serum levels of the target molecules were quantified utilizing enzyme-linked immunosorbent assay kits. Autism severity and behavioral traits were evaluated utilizing the Childhood Autism Rating Scale (CARS) and the Autism Behavior Checklist (AuBC).Results: Serum concentrations of Dkk-1 and PORCN were significantly higher in the ASD group relative to controls. However, no significant difference for serum Notum and Tiki-1 levels was detected between the groups. Correlation analyses revealed significant positive associations between serum PORCN, Notum, and Tiki-1 levels and multiple AuBC subscale and total scores. No significant correlations were found between any of the molecules and CARS scores.Conclusion: These data indicate that regulators of the Wnt/β-catenin pathway, notably Dkk-1 and PORCN may play a potential role in the pathogenesis of ASD. This study presents new data confirming the significance of Wnt/β-catenin pathway regulators in ASD and underscores the necessity for further research.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"84-92"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolomic Profile in Children and Adolescents with Attention Deficit Hyperactivity Disorders. 儿童和青少年注意缺陷多动障碍的代谢组学特征。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2026-01-06 DOI: 10.9758/cpn.25.1344

Brijesh Kumar Yadav, Manendra Singh Tomar, Ankit Pateriya, Sujita Kumar Kar, Amit Arya, Ashutosh Shrivastava, Pawan Kumar Gupta

{"title":"Metabolomic Profile in Children and Adolescents with Attention Deficit Hyperactivity Disorders.","authors":"Brijesh Kumar Yadav, Manendra Singh Tomar, Ankit Pateriya, Sujita Kumar Kar, Amit Arya, Ashutosh Shrivastava, Pawan Kumar Gupta","doi":"10.9758/cpn.25.1344","DOIUrl":"10.9758/cpn.25.1344","url":null,"abstract":"Objective: Biological processes are the sum of metabolic reactions that result in intermediate and end metabolite products. These processes are the reflection of genetic regulation and are profoundly impacted by environmental influence and changes, including those associated with attention-deficit/hyperactivity disorder (ADHD). This study aimed to assess the untargeted plasma metabolomic profile of children and adolescents with ADHD and to compare them with healthy controls and to study associations of dysregulated metabolic parameters with the clinical and socio-demographic parameters of ADHD.Methods: This study involved 42 registered cases of ADHD among children aged 6 to 16 years, diagnosed based on DSM-5 criteria. Each case was matched by age and gender with 24 healthy controls. The severity of ADHD was evaluated using the ADHD Rating Scale, while behavioral issues were assessed through the Child Behavior Checklist. The gas chromatography-mass spectrometry technique was employed to examine changes in plasma metabolite content.Results: We identified a total of 45 metabolites in the ADHD subtypes, which exhibited altered levels compared to the control group. The content of these metabolites and associated metabolic pathways showed significant differences between ADHD subjects and controls. Furthermore, we analyzed biomarkers derived from the compounds with the greatest fold changes in accumulation levels.Conclusion: The identification and analysis of these metabolites and metabolic pathways represent a promising new approach for tracking disease progression in ADHD. The findings of this study indicate that metabolite-based biomarkers may hold considerable potential for effective disease management.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"151-165"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lingual Dyskinesia Developing after the First Dose of Methylphenidate Treatment in a Child with Neurodevelopmental Disorders: Genetic Predispositions. 神经发育障碍儿童首次服用哌甲酯治疗后出现语言运动障碍：遗传易感性。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-09-11 DOI: 10.9758/cpn.25.1317

Duygu Karagöz, Hediye İlayda Ziyan Kurt, Nilfer Şahin

{"title":"Lingual Dyskinesia Developing after the First Dose of Methylphenidate Treatment in a Child with Neurodevelopmental Disorders: Genetic Predispositions.","authors":"Duygu Karagöz, Hediye İlayda Ziyan Kurt, Nilfer Şahin","doi":"10.9758/cpn.25.1317","DOIUrl":"10.9758/cpn.25.1317","url":null,"abstract":"Methylphenidate is generally well tolerated, but it often causes sleep disturbances, less commonly suppresses appetite, and may lead to neurological and movement disorders such as tics, dyskinesia, and psychosis. Among movement disorders, acute dyskinesias are particularly rare but clinically significant, as highlighted in recent pharmacovigilance data. Dopamine receptor hypersensitivity and excessive dopamine signaling, disturbances in other neurotransmitter systems, and genetic predisposition are some of the mechanisms thought to contribute to dyskinesia. In the literature, most cases of dyskinesia reported with methylphenidate consist of orofacial and limb dyskinesias or a combination of these. Additionally, acute cases of dyskinesia have been reported following the combined use of methylphenidate and sodium valproate in childhood. To our knowledge, our case is the first case of isolated lingual dyskinesia in which similar drug-related movement disorders are also identified in the family. It is known that the patient's mother also experienced acute movement disorders after taking psychotropic drugs. Furthermore, the presence of epilepsy diagnosis, sodium valproate use, and multiple neurodevelopmental disorders in our case is noteworthy. While our case demonstrates that dyskinesia can occur even at standard low treatment doses after the first dose, it emphasizes the importance of considering dyskinesia as a potential side effect in cases with a family history of similar drug-related side effects and epilepsy comorbidity.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"197-201"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives. 布雷哌唑治疗阿尔茨海默病引起的痴呆相关躁动：临床观点

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-12-30 DOI: 10.9758/cpn.24.1252

Hayeon Kim, Kyung Ho Lee, Changsu Han, Ashwin A Patkar, Prakash S Masand, Won-Myong Bahk, Chi-Un Pae

{"title":"Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.","authors":"Hayeon Kim, Kyung Ho Lee, Changsu Han, Ashwin A Patkar, Prakash S Masand, Won-Myong Bahk, Chi-Un Pae","doi":"10.9758/cpn.24.1252","DOIUrl":"10.9758/cpn.24.1252","url":null,"abstract":"Dementia is a neuropsychiatric disorder that primarily affects the elderly, leading to a widespread decline in cognitive function and significant impairment of occupational, social, and personal functioning. In addition to cognitive deficits, dementia is frequently comorbid with behavioral and psychological symptoms of dementia (BPSD), such as agitation. When present, these secondary symptoms can exacerbate the clinical course of the disease, reduced treatment responsiveness, increased rates of admission to long-term care facilities, extended hospitalization, higher risk of personal injury and a substantial socioeconomic burden. Given these consequences, early management of BPSD-particularly agitation-is critical to mitigating these risks. Although antipsychotics are commonly prescribed to manage agitation, risperidone remains the only agent approved by regulatory authorities for this indication. Recently, however, brexpiprazole, a medication with a pharmacological profile distinct from that of risperidone, received U.S. FDA approval (on May 11, 2023) for the treatment of agitation associated with Alzheimer's disease. Agitation is among the most prevalent BPSD manifestations, with symptoms ranging from verbal to physical aggression. Given its recent approval and unique pharmacodynamic properties, brexpiprazole may have strong potential as a therapeutic option for this population. This paper aims to review the pharmacological mechanisms, clinical evidence, and future perspectives of brexpiprazole as a novel therapeutic option for managing agitation in patients with Alzheimer's disease.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"15-29"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of Transcranial Random Noise Stimulation in Psychiatric Disorders: A Systematic Review. 经颅随机噪声刺激治疗精神疾病的安全性和有效性：一项系统综述。

IF 2.7 4区医学

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-02-28 Epub Date: 2025-12-04 DOI: 10.9758/cpn.25.1341

Adarsh Tripathi, Pritanshi Jeswani, Surobhi Chatterjee, Rini Joseph, Sujita Kumar Kar

{"title":"Safety and Efficacy of Transcranial Random Noise Stimulation in Psychiatric Disorders: A Systematic Review.","authors":"Adarsh Tripathi, Pritanshi Jeswani, Surobhi Chatterjee, Rini Joseph, Sujita Kumar Kar","doi":"10.9758/cpn.25.1341","DOIUrl":"10.9758/cpn.25.1341","url":null,"abstract":"Background: Transcranial random noise stimulation (tRNS) is a non-invasive brain stimulation technique that modulates cortical excitability through stochastic resonance. While promising, its safety and efficacy in psychiatric disorders remain underexplored.Objective: To systematically evaluate the efficacy and safety of tRNS in various psychiatric disorders.Methods: A systematic review was conducted per PRISMA guidelines and registered on PROSPERO (CRD420251040192). Databases searched included CENTRAL-Cochrane Central Register of Controlled Trials, PubMed, Scopus, and Web of Science. Studies were included from their inception to 30th April, 2025. Studies involving tRNS in psychiatric populations, regardless of study design, were included. The risk of bias was assessed using JBI tools.Results: 22 studies were included (642 individuals), spanning ADHD, depression, schizophrenia, dyslexia, and other conditions. Most studies used 20-minute tRNS sessions over 1-4 weeks. ADHD and dyslexia showed consistent improvements in overall executive function and reading & phonological skills, respectively. Schizophrenia studies demonstrated significant reductions in negative symptoms and auditory hallucinations. Effects in depression were mixed, with some studies reporting substantial symptom relief, while others found no significant benefit. Across disorders, tRNS was generally well-tolerated with only mild, transient adverse effects.Conclusion: tRNS appears to be a safe, well-tolerated, and potentially effective intervention for specific psychiatric symptoms, especially in ADHD, dyslexia, and schizophrenia. However, inconsistent protocols and mixed outcomes in mood disorders highlight the need for standardized protocols and further research.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 1","pages":"40-57"},"PeriodicalIF":2.7,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0